Literature DB >> 26382596

Antifungal antibiotics modulate the pro-inflammatory cytokine production and phagocytic activity of human monocytes in an in vitro sepsis model.

Stefan Muenster1, Christian Bode2, Britta Diedrich3, Sebastian Jahnert2, Christina Weisheit2, Folkert Steinhagen2, Stilla Frede2, Andreas Hoeft2, Rainer Meyer4, Olaf Boehm2, Pascal Knuefermann2, Georg Baumgarten2.   

Abstract

AIMS: The incidence of secondary systemic fungal infections has sharply increased in bacterial septic patients. Antimycotics exhibit immunomodulatory properties, yet these effects are incompletely understood in secondary systemic fungal infections following bacterial sepsis. We investigated a model of systemic inflammation to determine whether antimycotics (liposomal amphotericin B (L-AMB), itraconazol (ITC), and anidulafungin (ANI)) modulate the gene and protein expression as well as the phagocytic activity of lipopolysaccharide (LPS)-stimulated human monocytes. MAIN
METHODS: THP-1 monocytes were incubated with L-AMB, ITC or ANI and LPS. Gene expression levels of cytokines (TNF-<alpha>, IL-1<beta>, IL-6, and IL-10) were measured after 2h, 6h, and 24h. Cytokine protein levels were evaluated after 24h and phagocytic activity was determined following co-incubation with Escherichia coli. KEY
FINDINGS: All antimycotics differentially modulated the gene and protein expression of cytokines in sepsis-like conditions. In the presence of LPS, we identified L-AMB as immunosuppressive, whereas ITC demonstrated pro-inflammatory properties. Both compounds induced remarkably less phagocytosis. SIGNIFICANCE: Our study suggests that antimycotics routinely used in septic patients alter the immune response in sepsis-like conditions by modulating cytokine gene and protein expression levels and phagocytic activity. Future treatment strategies should consider the immune status of the host and apply antimycotics accordingly in bacterial septic patients with secondary fungal infections.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amphotericin B; Anidulafungin; Immunomodulation; Itraconazole; Phagocytosis; Sepsis

Mesh:

Substances:

Year:  2015        PMID: 26382596     DOI: 10.1016/j.lfs.2015.09.004

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

2.  Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer.

Authors:  David E Gerber; William C Putnam; Farjana J Fattah; Kemp H Kernstine; Rolf A Brekken; Ivan Pedrosa; Rachael Skelton; Jessica M Saltarski; Robert E Lenkinski; Richard D Leff; Chul Ahn; Chyndhri Padmanabhan; Vaidehi Chembukar; Sahba Kasiri; Raja Reddy Kallem; Indhumathy Subramaniyan; Qing Yuan; Quyen N Do; Yin Xi; Scott I Reznik; Lorraine Pelosof; Brandon Faubert; Ralph J DeBerardinis; James Kim
Journal:  Clin Cancer Res       Date:  2020-08-26       Impact factor: 12.531

3.  Impaired anti-fibrotic effect of bone marrow-derived mesenchymal stem cell in a mouse model of pulmonary paracoccidioidomycosis.

Authors:  Julián Camilo Arango; Juan David Puerta-Arias; Paula Andrea Pino-Tamayo; Lina María Salazar-Peláez; Mauricio Rojas; Ángel González
Journal:  PLoS Negl Trop Dis       Date:  2017-10-17

4.  Vancomycin and daptomycin modulate the innate immune response in a murine model of LPS-induced sepsis.

Authors:  Stefan Muenster; Valentina Zschernack; Birte Dierig; Stilla Frede; Georg Baumgarten; Mark Coburn; Christian Putensen; Christina Katharina Weisheit
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.